RCT · 2013
Efficacy of Thymosin Alpha 1 in Severe Sepsis (ETASS)
Wu J, Zhou L, Liu J, et al. · Critical Care
A 361-patient multicenter RCT reporting reduced 28-day mortality with thymosin alpha-1 added to standard sepsis care.
Key findings
- 28-day mortality 26.0% vs 35.0%
- Improved monocyte HLA-DR expression
- No significant adverse-event excess
Limitations
Single-country cohort, open-label design, and a subsequent larger trial produced more equivocal results.